To our knowledge, no reports have described nonhuman primate (NHP) models of frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) that do not depend on an overexpression paradigm. Based on our recent success in generating single human MAPT knock-in mouse models of FTDP-17, we describe the experimental basis for generating knock-in marmoset models of FTDP-17. In addition, successful generation of mutant PSEN1 knock-in marmoset models lacking exon 9 (PSEN1-Δ9) of Alzheimer's disease (AD) indicates that we will be able to reconstitute two major pathological features of AD, i.e., amyloid plaques and neurofibrillary tangles, in an accelerated manner by combining these models.
FengGJensenFEGreelyHT, et al.Opportunities and limitations of genetically modified nonhuman primate models for neuroscience research. Proc Natl Acad Sci U S A2020; 117: 24022–24031.
2.
Izpisua BelmonteJCCallawayEMCaddickSJ, et al.Brains, genes, and primates. Neuron2015; 86: 617–631.
3.
KishiNSatoKSasakiE, et al.Common marmoset as a new model animal for neuroscience research and genome editing technology. Dev Growth Differ2014; 56: 53–62.
4.
OkanoH. Current status of and perspectives on the application of marmosets in neurobiology. Annu Rev Neurosci2021; 44: 27–48.
5.
OkanoHKishiN. Investigation of brain science and neurological/psychiatric disorders using genetically modified non-human primates. Curr Opin Neurobiol2018; 50: 1–6.
6.
OkanoHMiyawakiAKasaiK. Brain/MINDS: brain-mapping project in Japan. Philos Trans R Soc Lond B Biol Sci2015; 370: 20140310.
7.
KanaanNMGrabinskiT. Neuronal and glial distribution of tau protein in the adult rat and monkey. Front Mol Neurosci2021; 14: 607303.
8.
SasaguriHHashimotoSWatamuraN, et al.Recent advances in the modeling of Alzheimer's disease. Front Neurosci2022; 16: 807473.
9.
WangYMandelkowE. Tau in physiology and pathology. Nat Rev Neurosci2016; 17: 5–21.
10.
SharmaGHuoAKimuraT, et al.Tau isoform expression and phosphorylation in marmoset brains. J Biol Chem2019; 294: 11433–11444.
11.
SaitoTMihiraNMatsubaY, et al.Humanization of the entire murine Mapt gene provides a murine model of pathological human tau propagation. J Biol Chem2019; 294: 12754–12765.
12.
WatamuraNFoianiMSBezS, et al.In vivo hyperphosphorylation of tau is associated with synaptic loss and behavioral abnormalities in the absence of tau seeds. Nat Neurosci. Epub ahead of print 24 Dec 2024. DOI: https://doi.org/10.1038/s41593-024-01829-7
13.
AnzaloneAVKoblanLWLiuDR. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol2020; 38: 824–844.
14.
KomorACZhaoKTPackerMS, et al.Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:g-to-T:a base editors with higher efficiency and product purity. Sci Adv2017; 3: eaao4774.
15.
LiangPDingCSunH, et al.Correction of beta-thalassemia mutant by base editor in human embryos. Protein Cell2017; 8: 811–822.
16.
LiangPSunHSunY, et al.Effective gene editing by high-fidelity base editor 2 in mouse zygotes. Protein Cell2017; 8: 601–611.
17.
SasaguriHNagataKSekiguchiM, et al.Introduction of pathogenic mutations into the mouse Psen1 gene by base editor and target-AID. Nat Commun2018; 9: 2892. 05262-w.
18.
HuttonMLendonCLRizzuP, et al.Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature1998; 393: 702–705.
19.
PoorkajPBirdTDWijsmanE, et al.Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol1998; 43: 815–825.
20.
SpillantiniMGMurrellJRGoedertM, et al.Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A1998; 95: 7737–7741.
21.
ForrestSLKrilJJHallidayGM. Cellular and regional vulnerability in frontotemporal tauopathies. Acta Neuropathol2019; 138: 705–727.
22.
ShiYZhangWYangY, et al.Structure-based classification of tauopathies. Nature2021; 598: 359–363.
23.
BronnerIFter MeulenBCAzmaniA, et al.Hereditary Pick's disease with the G272 V tau mutation shows predominant three-repeat tau pathology. Brain2005; 128: 2645–2653.
24.
GeulaCNagykeryNWuCK. Amyloid-beta deposits in the cerebral cortex of the aged common marmoset (Callithrix jacchus): incidence and chemical composition. Acta Neuropathol2002; 103: 48–58.
25.
Rodriguez-CallejasJDFuchsEPerez-CruzC. Evidence of tau hyperphosphorylation and dystrophic microglia in the common marmoset. Front Aging Neurosci2016; 8: 315.
26.
Rodriguez-CallejasJDFuchsEPerez-CruzC. Corrigendum: evidence of tau hyperphosphorylation and dystrophic microglia in the common marmoset. Front Aging Neurosci2017; 9: 32.
27.
Rodríguez-CallejasJDFuchsEPerez-CruzC. Atrophic astrocytes in aged marmosets present tau hyperphosphorylation, RNA oxidation, and DNA fragmentation. Neurobiol Aging2023; 129: 121–136.
28.
MichaelsonDM. APOE Epsilon4: the most prevalent yet understudied risk factor for Alzheimer's disease. Alzheimers Dement2014; 10: 861–868.
29.
MorrisJCRoeCMXiongCJ, et al.APOE Predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol2010; 67: 122–131.
30.
SaidoTC. Alzheimer's disease research guide: Animal models for understanding mechanisms and medications. Cambridge, MA: Elsevier Inc, 2024.
31.
SaitoTMatsubaYMihiraN, et al.Single app knock-in mouse models of Alzheimer's disease. Nat Neurosci2014; 17: 661–663.
32.
SatoKSasaguriHKumitaW, et al.Production of a heterozygous exon skipping model of common marmosets using gene-editing technology. Lab Anim (NY)2024; 53: 244–251.
33.
HiguchiM. Tau PET imaging. Adv Exp Med Biol2019; 1184: 217–230.
34.
HiguchiMMaedaJJiB, et al.PET Applications in animal models of neurodegenerative and neuroinflammatory disorders. Curr Top Behav Neurosci2012; 11: 45–64.
35.
MoriTMaedaJShimadaH, et al.Molecular imaging of dementia. Psychogeriatrics2012; 12: 106–114.
36.
SaharaNHiguchiM. Diagnostic and therapeutic targeting of pathological tau proteins in neurodegenerative disorders. FEBS Open Bio2024; 14: 165–180.
37.
SaharaNMaedaJIshikawaA, et al.Microglial activation during pathogenesis of tauopathy in rTg4510 mice: implications for the early diagnosis of tauopathy. J Alzheimers Dis2018; 64: S353–S359.
38.
ShimojoMHiguchiMSuharaT, et al.Imaging multimodalities for dissecting Alzheimer's disease: advanced technologies of positron emission tomography and fluorescence imaging. Front Neurosci2015; 9: 482.
39.
IshigakiSFujiokaYOkadaY, et al.Altered tau isoform ratio caused by loss of FUS and SFPQ function leads to FTLD-like phenotypes. Cell Rep2017; 18: 1118–1131.
40.
BhattacherjeeARodriguesEJungJ, et al.Repression of phagocytosis by human CD33 is not conserved with mouse CD33. Commun Biol2019; 2: 450.
41.
JacksonHMFoleyKEO'RourkeR, et al.A novel mouse model expressing human forms for complement receptors CR1 and CR2. BMC Genet2020; 21: 101.
42.
AravalliRNCollinsDPHapkeJH, et al.Hepatic differentiation of marmoset embryonic stem cells and functional characterization of ESC-derived hepatocyte-like cells. Hepat Med2020; 12: 15–27.
43.
AravalliRNSteerCJ. Utility of common marmoset (Callithrix jacchus) embryonic stem cells in liver disease modeling, tissue engineering and drug metabolism. Genes (Basel)2020; 11: 729.
44.
BayurovaEZhitkevichAAvdoshinaD, et al.Common marmoset cell lines and their applications in biomedical research. Cells2023; 12: 2020.
45.
KishimotoKShimadaAShinoharaH, et al.Establishment of novel common marmoset embryonic stem cell lines under various conditions. Stem Cell Res2021; 53: 102252.
46.
SasakiEHanazawaKKuritaR, et al.Establishment of novel embryonic stem cell lines derived from the common marmoset (Callithrix jacchus). Stem Cells2005; 23: 1304–1313.
47.
ShiozawaSNakajimaMOkaharaJ, et al.Primed to naive-like conversion of the common marmoset embryonic stem cells. Stem Cells Dev2020; 29: 761–773.
48.
ShonoMKishimotoKHikabeO, et al.Induction of primordial germ cell-like cells from common marmoset embryonic stem cells by inhibition of WNT and retinoic acid signaling. Sci Rep2023; 13: 3186.
49.
YoshimatsuSMurakamiRSatoT, et al.Generation of a common marmoset embryonic stem cell line CMES40-OC harboring a POU5F1 (OCT4)-2A-mCerulean3 knock-in reporter allele. Stem Cell Res2021; 53: 102308.
50.
YoshimatsuSNakajimaMSonnI, et al.Attempts for deriving extended pluripotent stem cells from common marmoset embryonic stem cells. Genes Cells2023; 28: 156–169.
51.
TomiokaIMaedaTShimadaH, et al.Generating induced pluripotent stem cells from common marmoset (Callithrix jacchus) fetal liver cells using defined factors, including Lin28. Genes Cells2010; 15: 959–969.
52.
ShimadaHSatoYSasakiT, et al.A next-generation iPSC-derived forebrain organoid model of tauopathy with tau fibrils by AAV-mediated gene transfer. Cell Rep Methods2022; 2: 100289.
53.
GuardigniMPruccoliLSantiniA, et al.PROTAC-induced glycogen synthase kinase 3β degradation as a potential therapeutic strategy for Alzheimer's disease. ACS Chem Neurosci2023; 14: 1963–1970.
54.
InuzukaHLiuJWeiW, et al.PROTACs technology for treatment of Alzheimer's disease: advances and perspectives. Acta Mater Med2022; 1: 24–41.
55.
Jangampalli AdiPReddyPH. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies. Biochim Biophys Acta Mol Basis Dis2021; 1867: 166162.
56.
KargboRB. Treatment of Alzheimer's by PROTAC-tau protein degradation. ACS Med Chem Lett2019; 10: 699–700.
57.
MaKHanXXYangXM, et al.Proteolysis targeting chimera technology: a novel strategy for treating diseases of the central nervous system. Neural Regen Res2021; 16: 1944–1949.
58.
TashimaT. Proteolysis-targeting chimera (PROTAC) delivery into the brain across the blood-brain barrier. Antibodies (Basel)2023; 12: 43.
59.
WangWZhouQJiangT, et al.A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models. Theranostics2021; 11: 5279–5295.
